Core Insights - The company reported a strong performance in H1 2025, with like-for-like sales growth of +4.2% driven by a volume/mix increase of +2.6% and price growth of +1.7% [7][9] - Recurring operating income increased by +3.7% to €1,811 million, with a recurring operating margin of 13.2%, up +49 basis points from the previous year [17] - The company confirmed its 2025 guidance, expecting like-for-like sales growth between +3% and +5%, with recurring operating income anticipated to grow faster than sales [22] Financial Performance - H1 2025 sales were reported at €13,737 million, a slight decrease of -0.1% on a reported basis, primarily due to negative currency impacts [9][21] - Recurring net income attributable to the Group increased by +5.9% to €1,231 million, while total net income decreased by -14.7% to €1,040 million due to non-recurring expenses [19][20] - Free cash flow for H1 2025 was €1,172 million, down -6.1% from the previous year [21] Segment Performance - Sales in Europe increased by +2.3% in H1 2025, with strong growth in Dairy and Plant-based products [10][11] - North America saw a decline in sales by -4.6% on a reported basis, but like-for-like sales grew by +3.0% [10][11] - China, North Asia & Oceania experienced robust growth, with sales up +11.3% on a like-for-like basis, driven by strong performance in Specialized Nutrition [12][13] Strategic Developments - The company is actively investing in its portfolio, including the acquisition of Kate Farms and The Akkermansia Company, to enhance its health-focused offerings [4][30] - The CEO emphasized the importance of a consumer-centric and science-based strategy to drive future growth [5][3] - The company remains committed to its Renew Danone strategy, focusing on high protein, medical nutrition, and plant-based products [4][3]